Minerva Neurosciences Inc

4MNA

Company Profile

  • Business description

    Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

  • Contact

    1500 District Avenue
    BurlingtonMA01803
    USA

    T: +1 617 600-7373

    E: [email protected]

    https://www.minervaneurosciences.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    8

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,510.7043.700.52%
CAC 407,873.8323.730.30%
DAX 4023,638.5672.020.31%
Dow JONES (US)42,140.43269.67-0.64%
FTSE 1008,602.922.06-0.02%
HKSE23,108.27441.19-1.87%
NASDAQ19,010.09301.741.61%
Nikkei 22538,183.26539.001.43%
NZX 50 Index12,781.205.54-0.04%
S&P 5005,886.5542.360.72%
S&P/ASX 2008,269.0035.500.43%
SSE Composite Index3,374.875.630.17%

Market Movers